Arcutis Biotherapeutics, Inc. (ARQT) vs Xenon Pharmaceuticals Inc. (XENE)
- Arcutis Biotherapeutics, Inc. ARQT 28.82 −0.96%
- Xenon Pharmaceuticals Inc. XENE 33.55 −2.27%
Arcutis Biotherapeutics, Inc. and Xenon Pharmaceuticals Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. is the larger, with a market value of $3.7B against $3.3B — 1.1× the size. Xenon Pharmaceuticals Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 131×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against −8.15%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs 0.00%) and the higher return on invested capital (23.6% vs −88.5%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 13 and Xenon Pharmaceuticals Inc. on 4.
Valuation
Profitability
| Metric | ARQT | XENE | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 28.40% | 65.16% |
| Operating margin | 7.38% | 0.00% | 0.00% |
| Net margin | 6.15% | 0.00% | 0.00% |
| Free cash flow margin | 8.42% | 0.00% | 0.00% |
| Return on equity | 15.86% | (43.62%) | (56.36%) |
| Return on assets | 6.78% | (41.54%) | (48.04%) |
| Return on invested capital | 23.62% | (88.54%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack